TSHA Stock Price | Taysha Gene Therapies Inc P/E, Revenue, EPS, & Forecasts

Taysha Gene Therapies Inc • TSHA

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Taysha Gene Therapies Inc

Ticker

TSHA

Trading on

NASDAQ

ISIN

US8776191061

Industry

Biotechnology

Sector

Healthcare

CEO

Sean P. Nolan

Headquarters

3000 Pegasus Park Drive, Dallas, TX, United States, 75247

Employees

Website

tayshagtx.com

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Metrics

BasicAdvanced

Market cap

$1.05B

P/E ratio

EPS

-$0.33

Dividend Yield

0.00%

Beta

1.03

Forward P/E ratio

EBIDTA

$-101M

Ex dividend date

Price & volume

Market cap

$1.05B

Average daily volume

4.2M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

166.26

Price to book

5.35

Earnings

EPS

-$0.33

EPS estimate (current quarter)

-$0.09

EPS estimate (next quarter)

-$0.10

EBITDA

$-101M

Revenues (TTM)

$6.3M

Revenues per share (TTM)

$0.02

Technicals

Beta

1.03

52-week High

$5.51

52-week Low

$1.05

50-day moving average

$3.99

200-day moving average

$2.62

Short ratio

3.96

Short %

17.20%

Management effectiveness

ROE (TTM)

-64.93%

ROA (TTM)

-25.70%

Profit margin

0.00%

Gross profit margin

$6.3M

Operating margin

-1,618.54%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

78.60%

Share stats

Outstanding Shares

274M

Float

175M

Insiders %

11.04%

Institutions %

95.18%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 10 analysts.

Average price target

$10.08

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.07

-$0.08

12.50%

Q4 • 24Beat

-$0.07

-$0.09

22.22%

Q1 • 25Beat

-$0.08

-$0.07

-14.29%

Q2 • 25Missed

-$0.09

-$0.08

-9.38%

Q3 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$2M

$-26.9M

-1,353.58%

Q2 • 25

$-32.7M

0.00%

Q3 • 25

NaN%

21.77%

0.00%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$333M

$84.6M

25.38%

Q2 • 25

$317M

$97.6M

30.82%

Q3 • 25

-5.03%

15.32%

21.43%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-20.2M

$0.1M

$216M

$-20.2M

Q2 • 25

$-24.2M

$8.8M

$-24.3M

Q3 • 25

19.74%

-95.93%

20.26%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Taysha Gene Therapies Inc share?

Taysha Gene Therapies Inc shares are currently traded for undefined per share.

How many shares does Taysha Gene Therapies Inc have?

Taysha Gene Therapies Inc currently has 274M shares.

Does Taysha Gene Therapies Inc pay dividends?

No, Taysha Gene Therapies Inc doesn't pay dividends.

What is Taysha Gene Therapies Inc 52 week high?

Taysha Gene Therapies Inc 52 week high is $5.51.

What is Taysha Gene Therapies Inc 52 week low?

Taysha Gene Therapies Inc 52 week low is $1.05.

What is the 200-day moving average of Taysha Gene Therapies Inc?

Taysha Gene Therapies Inc 200-day moving average is $2.62.

Who is Taysha Gene Therapies Inc CEO?

The CEO of Taysha Gene Therapies Inc is Sean P. Nolan.

How many employees Taysha Gene Therapies Inc has?

Taysha Gene Therapies Inc has 73 employees.

What is the market cap of Taysha Gene Therapies Inc?

The market cap of Taysha Gene Therapies Inc is $1.05B.

What is the P/E of Taysha Gene Therapies Inc?

The current P/E of Taysha Gene Therapies Inc is null.

What is the EPS of Taysha Gene Therapies Inc?

The EPS of Taysha Gene Therapies Inc is -$0.33.

What is the PEG Ratio of Taysha Gene Therapies Inc?

The PEG Ratio of Taysha Gene Therapies Inc is null.

What do analysts say about Taysha Gene Therapies Inc?

According to the analysts Taysha Gene Therapies Inc is considered a buy.